论文部分内容阅读
目的探讨肺纤方提取物对肺间质纤维化大鼠肺纤维化程度和肺微血管变化和血小板-内皮黏附因子31、34(CD31、CD34)表达的影响。方法将大鼠分为假手术组、模型组、泼尼松组、氯沙坦组和肺纤方大、中、小剂量组,共7组。除假手术组外,采用气管插管灌注博莱霉素3 mg/kg进行大鼠肺间质纤维化造模;造模第2天予以不同药物灌胃干预。于14、28 d分两批进行动物处理,电镜观察肺纤维化程度和肺微血管变化,免疫组化检测CD31、CD34表达。结果肺纤方大、中剂量组均能抑制肺泡炎、纤维化程度及微血管密度,较模型组有显著差异(P<0.05)。结论肺纤方通过减轻肺纤维化微血管密度表达,减少肺泡炎时的异常血管新生,而具有抗肺间质纤维化作用。
Objective To investigate the effects of Fei Xian Fu Fang on pulmonary fibrosis and pulmonary microvascular changes and the expression of platelet-endothelium adhesion molecules 31, 34 (CD31, CD34) in rats with pulmonary fibrosis. Methods The rats were divided into sham-operation group, model group, prednisone group, losartan group, and fibrofiberium-treated group, with a total of 7 groups. In addition to sham operation group, intratracheal intratracheal instillation of bleomycin 3 mg / kg for pulmonary interstitial fibrosis in rats; Animals were treated in two batches on 14 and 28 days. The degree of pulmonary fibrosis and pulmonary microvascular changes were observed by electron microscope. The expressions of CD31 and CD34 were detected by immunohistochemistry. Results Pulmonary fibrosis large, medium dose group can inhibit alveolitis, fibrosis and microvessel density, compared with the model group were significantly different (P <0.05). Conclusion Feixian Prescription has anti-pulmonary interstitial fibrosis by reducing the expression of microvessel density in pulmonary fibrosis and reducing the abnormal angiogenesis in alveolitis.